SEC filing · 8-K

Azenta, Inc.: Asset write-down

Azenta approved a restructuring plan in its Multiomics segment that includes closing three North American laboratories and reducing workforce.

Filed October 7, 2026

Mixed for the company

What happened

On October 5, 2026, the Board of Directors approved a restructuring plan within the Multiomics segment.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Azenta, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.